APOE ε4 dosage association with AD risk did not reveal differences between the MAPT H2 non‐carriers (OR = 1.35, P = 3.28E‐264) and H2 carriers (OR = 1.42, P = 2.80E‐190). Here, APOE is linked to Alzheimer disease.